Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference38 articles.
1. Xia P, Xu X-Y. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5:1602–9.
2. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.
3. Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, et al. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci USA. 2017;114:7095–100.
4. Mollon LE, Anderson EJ, Dean JL, Warholak TL, Aizer A, Platt EA, et al. A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR+/HER2− metastatic breast cancer. Clin Breast Cancer. 2020;20:e232–43.
5. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5:921–9.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献